ArticleArchives of medical science : AMS2022
Bergamottin exerts anticancer effects on human colon cancer cells via induction of apoptosis, G2/M cell cycle arrest and deactivation of the Ras/Raf/ERK signalling pathway.
Article in Archives of medical science : AMS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 12 citations in OpenAlex.
- Bergamottin pretreatment attenuates cisplatin-induced acute kidney injury in mice by inhibiting BACE-1-mediated ferroptosis.Renal failure · 2026Article
- Bergamottin: a multitarget natural furanocoumarin with promising anticancer potential.Translational cancer research · 2026Review
- Bergamottin demonstrates preclinical effectiveness against pancreatic cancer by modulating PPAR-γ to induce apoptosis.Translational cancer research · 2026Article
- Coumarins fromOncoTargets and therapy · 2025Article
- Chitosan oligosaccharide enhances the anti-cancer effects of 5-fluorouracil on SNU-C5 colorectal cancer cells by activating ERK.Oncology research · 2025Article
- CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies.Cancer science · 2024Article
- Bergamottin (Ber) ameliorates the progression of osteoarthritis via the Sirt1/NF-κB pathway.Frontiers in pharmacology · 2024Article
- Therapeutic Potential of Essential Oils Against Ulcerative Colitis: A Review.Journal of inflammation research · 2024Review
- Bergamottin Inhibits PRRSV Replication by Blocking Viral Non-Structural Proteins Expression and Viral RNA Synthesis.Viruses · 2023Article
- The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer.Archives of medical science : AMS · 2023Article
- Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects.International journal of molecular sciences · 2020Review
- MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.American journal of translational research · 2020Article
- Unveiling the Anticancer Potential and Molecular Mechanisms of Fangchinoline Against Cholangiocarcinoma Using FTIR Microspectroscopy, In Vitro and In Silico Approaches.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accumulating evidence has shown the potential of bergamottin as an anticancer agent. The present study was undertaken to evaluate the anticancer affects of bergamottin (μM) against colon cancer cells. Material and methods: Antiproliferative effects were evaluated by WST-1 cell viability assay. Apoptotic effects were studied by DAPI and Annexin V/PI staining. Cell cycle analysis was carried out by flow cytometry. Transwell assay was used to study the effects on cell invasion. Protein expression was estimated by the western blot method. Results: The results showed that bergamottin suppresses the proliferation of all the human colon cancer cell lines. Nonetheless, the growth inhibitory effects of bergamottin on the HT-29 and RKO cells were more significant (IC50, 12.5 μM). The anticancer effects of bergamottin on the HT-29 and RKO cells were mainly due to apoptosis. Bergamottin could considerably increase the expression of Bax and reduce the expression Bcl-2. The cleavage of caspase-3, 8 and 9 was also enhanced upon bergamottin treatment of the colon cancer cells. Flow cytometric analysis showed that bergamottin also induced G2/M cell cycle arrest of the HT-29 and RKO cells. Additionally, bergamottin could also suppress the invasion of HT-29 and RKO cells. The Raf/MEK/ERK pathway is regarded as one of the essential pathways involved in the development and progression of cancers. Herein, it was observed that bergamottin could concentration dependently block this pathway in colon cancer cells. Conclusions: Taken together, bergamottin suppresses the proliferation of colon cancer cells and may be utilised in the development of chemotherapy for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.